NEW YORK (GenomeWeb News) – Sanford-Burnham Medical Research Institute and Intrexon have struck a collaboration focused on developing new induced pluripotent stem cell technologies for research purposes, the institute said today.

Under the plan, Sanford-Burnham researchers will use Intrexon's RheoSwitch Therapeutic System (RTS) and its Laser-Enabled Analysis and Processing (LEAP) instrument for cellular selection and gene regulation purposes. Intrexon may obtain commercial and intellectual property rights to technologies that result from the partnership, Sanford-Burnham said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.